INKT
HEALTHCAREMink Therapeutics Inc
AI Insight
What's Moving INKT Today?
No stock-specific AI insight has been generated for INKT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.80$76.00
$12.33
Fundamentals
Market Cap$61M
P/E Ratio—
EPS$-2.80
Dividend Yield—
Dividend / Share—
ROE-1,239.0%
Profit Margin—
Debt / Equity—
Trading
Volume23K
Avg Volume (10D)—
Shares Outstanding5.0M
INKT News
23 articles- MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders MeetingYahoo Finance·Jun 3, 2026
- MiNK Therapeutics (INKT) director receives RSUs for board payStock Titan·Jun 3, 2026
- Behavioral Patterns of INKT and Institutional FlowsStock Traders Daily·May 30, 2026
- MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical IllnessYahoo Finance·May 28, 2026
- MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology CommunicationsInvesting News Network·May 20, 2026
- We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn RateYahoo Finance·May 18, 2026
- Earnings Call Summary | MiNK Therapeutics(INKT.US) Q1 2026 Earnings ConferenceMoomoo·May 16, 2026
- MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ...Yahoo Finance·May 15, 2026
- MiNK (INKT) Q4 2025 Earnings Call TranscriptMotley Fool·May 15, 2026
- MiNK Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 15, 2026
- MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical ValidationYahoo Finance·May 15, 2026
- MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical IllnessYahoo Finance·May 14, 2026
- MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026Yahoo Finance·May 12, 2026
- MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy ProgramsYahoo Finance·May 8, 2026
- Agenus to Provide First Quarter 2026 Financial Report and Corporate UpdateYahoo Finance·May 4, 2026
- MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal CancerGlobeNewswire Inc.·Apr 17, 2026
- MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026GlobeNewswire Inc.·Apr 3, 2026
- Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026Yahoo Finance·Apr 3, 2026
- MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell TherapyYahoo Finance·Apr 2, 2026
- MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International ConferenceYahoo Finance·Apr 1, 2026
- MiNK Therapeutics Inc (INKT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ...Yahoo Finance·Mar 31, 2026
- MiNK Therapeutics, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 31, 2026
- MiNK Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 31, 2026
All 23 articles loaded
Price Data
Open$11.88
Previous Close$12.33
Day High$12.58
Day Low$11.88
52 Week High$76.00
52 Week Low$6.80
52-Week Range
$6.80$76.00
$12.33
Fundamentals
Market Cap$61M
P/E Ratio—
EPS$-2.80
Dividend Yield—
Dividend / Share—
ROE-1,239.0%
Profit Margin—
Debt / Equity—
Trading
Volume23K
Avg Volume (10D)—
Shares Outstanding5.0M
About Mink Therapeutics Inc
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic, ready-to-use, invariant natural killer T-cell therapies for treating cancer and other immune-mediated diseases. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—